IAJD34
Version 1.10353b77 · 2026-09-13
| CAS No. | Not available |
| Chemical Name | IAJD34 |
| Synonyms | IAJD-34， IAJD 34 |
| SMILES | CCCCCCCCCCCOC1=CC(OCCCCCCCCCCC)=CC(CNC(=O)C2=CC(OCCOCCOCCOC(=O)CCCN3CCCCC3)=C(OCCOCCOCCOCC3=CC=CC=C3)C(OCCOCCOCCOC(=O)CCCN3CCCCC3)=C2)=C1 |
| Formula | C79H129N3O17 |
| M.Wt | 1,392.91 |
| Purity | >98% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Meshanni, J.A., Stevenson, E.R., Zhang, D. et al. Targeted delivery of TGF-β mRNA to murine lung parenchyma using one-component ionizable amphiphilic Janus Dendrimers. Nat Commun 16, 1806 (2025). |
IAJD-34 is a one-component ionizable amphiphilic Janus dendrimer specifically engineered for targeted mRNA delivery to the lung parenchyma, as described by Meshanni et al. in Nature Communications article "Targeted delivery of TGF-β mRNA to murine lung parenchyma using one-component ionizable amphiphilic Janus Dendrimers" . This synthetic nanoparticle self-assembles with mRNA through simple mixing in acetate buffer, forming stable dendrimersomes approximately 93-97 nm in size with high encapsulation efficiency (>95%) and a positive zeta potential (~48 mV). Its defining feature, highlighted in the study, is exceptional lung tropism after intravenous injection, enabling significantly higher luciferase expression in murine lungs compared to other organs. As demonstrated by Meshanni et al., IAJD 34 effectively delivers therapeutic mRNA (e.g., TGF-β mRNA) to the lower lung, inducing transient protein production with minimal systemic toxicity at appropriate doses (e.g., 10 µg), offering a promising strategy for treating parenchymal lung diseases.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →